Compare IHT & ALZN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | IHT | ALZN |
|---|---|---|
| Founded | 1971 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Bankers/Brokers/Service | Medicinal Chemicals and Botanical Products |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.8M | 7.6M |
| IPO Year | 1995 | 2021 |
| Metric | IHT | ALZN |
|---|---|---|
| Price | $1.08 | $2.00 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $28.00 |
| AVG Volume (30 Days) | 11.9K | ★ 72.1K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | ★ 1.92% | N/A |
| EPS Growth | N/A | ★ 22.99 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $7,600,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 1.33 | N/A |
| 52 Week Low | $0.95 | $0.51 |
| 52 Week High | $4.24 | $8.22 |
| Indicator | IHT | ALZN |
|---|---|---|
| Relative Strength Index (RSI) | 37.64 | 49.40 |
| Support Level | $1.05 | $1.88 |
| Resistance Level | $1.27 | $2.59 |
| Average True Range (ATR) | 0.08 | 0.17 |
| MACD | -0.01 | 0.03 |
| Stochastic Oscillator | 40.63 | 71.13 |
InnSuites Hospitality Trust is a real estate investment trust. It is engaged in the ownership and operation of hotel properties. It owns and operates hotels, provides management services for hotels, and also provides trademark license services. The Trust is also involved in various operations incidental to the operation of hotels, such as the operation of restaurants, meeting/banquet room rentals, and the operation of a reservation system. It has one reportable segment Hotel Operations & Hotel Management Services.
Alzamend Neuro Inc is an early clinical-stage biopharmaceutical company. It is focused on developing novel products for the treatment of neurodegenerative diseases and psychiatric disorders, including Alzheimer's. Its mission is to develop and market safe and effective treatments. The company's pipeline consists of two novel therapeutic drug candidates, AL001 - a patented ionic cocrystal technology delivering lithium via a therapeutic combination of lithium, proline and salicylate, and AL002 - a patented method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine that seeks to restore the ability of a patient's immunological system to combat Alzheimer's.